Tilray to exit New Zealand medical cannabis market | Cannabis Law Report | Where to order Skittles Moonrock online

Learn where to order CBD online. TOP QUALITY GRADE A++

Cannabyss Inc. is the best place online to buy top quality weed, cannabis, vape, marijuana and CBD products. Get your borderless orders delivered at the pickup spot with ease. Top Grade products for client satisfaction.

👉 Click here to Visit our shop! 🛒

Press Release

Tilray Medical has confirmed they are leaving the New Zealand medical cannabis market to better focus on the Australian medical market.

The company recently confirmed its exit with New Zealand publication The Post, with its final day of sales in the country set for May 31.

Although the company was not immediately available for response to a media request from StratCann, they told The Post in a statement: “Our priority is to manage this transition effectively, minimising any disruption and ensuring Tilray patients in New Zealand have access to necessary treatments during and after the transition period.

“Zero Tilray employees were impacted by this strategic decision,” it added in the statement.

In Tilray Brands Inc.’s most recent quarterly report for the three months ended February 28, 2025 (Q3 2025), the company recognized US$0.3 million of restructuring charges related to its decision to exit the New Zealand medical cannabis market.

In 2021, the company became one of the first licensed cannabis producers to operate in New Zealand following 2020 legislation that created the country’s medical cannabis system. The company sold cannabis flower and extracts (oils) in New Zealand. The company received approval for its first limited shipment to New Zealand even earlier, in 2017.

On April 17, 2025, Tilray Medical announced its first launch of cannabis edibles in the Australian market.

Tilray to exit New Zealand medical cannabis market